ABT-263 Heals Aged Skin by Clearing Zombie Cells
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ABT-263, a topical senolytic drug tested by Boston University researchers, sped wound healing in aged mice — 80% of treated mice fully healed by day 24 vs. 56% of untreated controls.
- The treatment worked by clearing out 'zombie' senescent cells from aged skin and activating genes tied to collagen production, blood vessel growth, and tissue remodeling.
- ABT-263 briefly spiked inflammation in treated skin, a counterintuitive finding the researchers said helped 'wake up' sluggish healing pathways in older tissue.
- Topical application sidestepped the systemic side effects of oral senolytic drugs, and the treatment had no comparable effect in young mice — pointing to a specific action on accumulated senescent cells in aged skin.
- A 2026 follow-up study used an ABT-263 wound dressing in diabetic mice, reporting improved healing and no detectable systemic toxicity and extending the approach to diabetic wounds.
- The 2024 study, led by Maria Shvedova and Daniel S. Roh at Boston University's Chobanian and Avedisian School of Medicine, was published in the journal Aging.
Why it matters: The 80%-vs-56% healing advantage in older mice, achieved by clearing senescent cells with a topical drug, points to a new route for treating surgical and chronic wounds in older adults — a group at elevated risk of prolonged recovery and complications. The topical formulation specifically avoids the systemic toxicity that has limited oral senolytics in earlier work.
Ask SkimNews
